13.53
0.32 (2.42%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Contineum Therapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -1.5 |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.75 |
|
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.82% |
| 机构持股比例 | 79.99% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Johnson & Johnson | 30 Jun 2026 | 1,979,173 |
| Balyasny Asset Management L.P. | 30 Jun 2026 | 1,522,793 |
| Longaeva Partners L.P. | 30 Jun 2026 | 812,757 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| STENGONE CARMINE N. | - | 15.94 | -2,500 | -39,850 |
| 累积净数量 | -2,500 | |||
| 累积净值 ($) | -39,850 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 15.94 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| STENGONE CARMINE N. | 职员 | 08 Sep 2026 | 自动卖出 (-) | 2,500 | 15.94 | 39,850 |
| STENGONE CARMINE N. | 职员 | 08 Sep 2026 | 执行期权 | 2,500 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合